At this year’s European Society of Magnetic Resonance in Medicine and Biology (ESMRMB) congress, Professor Paul Hockings (Senior Director, MR Imaging at Antaros Medical) is presenting the design of the HEROIC study (Mccafferty K et al. 2020). This ongoing, observational, 5-year study investigates both kidney and cardiac magnetic resonance imaging (MRI) in a biopsy proven diabetic kidney disease (DKD) population. The study will give further insights on how kidney MRI can be used to assess kidney fibrosis as well as short- and long-term progression of DKD.
Tune in to the presentation at ESMRMB 2021:
Title: HEROIC: a 5-year observational cohort study of multi-ethnic patients with biopsy-proven DKD
Time: October 8, 2021 @ 09.40
Presenter: Paul Hockings, Senior Director, MR Imaging at Antaros Medical
About diabetic kidney disease
Today, Chronic Kidney Disease (CKD) affects around 10% of the world’s population. Diabetes Mellitus (DM) is one of the leading causes of CKD, where around 30-40% of DM patients develop DKD. In its most advanced stage, DKD requires renal replacement therapy (dialysis or kidney transplant) imposing a high burden on both healthcare and the quality of life of patients. With the global increase of DM, the burden of DKD is expected to continue to grow.
Currently used biomarkers for DKD allows estimation of kidney function, but biopsy is necessary to understand disease aetiology. Recent advances in the CKD and DKD field has allowed that treatments for these patients are now on the way. However, there is a huge need to find new, non-invasive biomarkers to guide the further development of drugs in this area. MRI has great potential to non-invasively assess functional and morphologic, including fibrotic, changes in the kidney that may improve diagnosis, prognosis, and treatment monitoring in patients with DKD.